TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03365622
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
Study: NCT04313868
Drug: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
Normalized name: Thymidine
DrugBank: Thymidine (DB04485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN2 is an investigational drug combining cytotoxic and immunotherapy.
Study: NCT01325233
Drug: PG2
Normalized name: Fossaoprin SPG2 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
Study: NCT01325233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml normal saline, tiw, 2 weeks
Study: NCT02571816
Drug: ASP2215
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03823534
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: An IV normal saline placebo prepared by the hospital pharmacy.
Study: NCT03823534
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 500 mg PO Q4 hours PRN for mild pain
Study: NCT03823534
Drug: Oxycodone Acetaminophen
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
Study: NCT03823534
Drug: Hydrocodone/Acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
Study: NCT02452242
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
Study: NCT02507323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00460785
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00881738
Drug: Clarithromycin 250 mg Tablets (Geneva, USA)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04587908
Drug: TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ・Treatment period：oral administration for 52 weeks, BID after meal
Study: NCT05113511
Drug: SCT510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.
Study: NCT00267215
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02575755
Drug: Azithromycin plus piperaquine phosphate
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04658329
Drug: Antiretroviral
Normalized name: Antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
Study: NCT01480622
Drug: TDF tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331
Study: NCT02498301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
Study: NCT03556137
Drug: [18F]FTC-146
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
Study: NCT01976936
Drug: Low Dose Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg daily for 3 days
Study: NCT01976936
Drug: High Dose Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 640 mg daily for 3 days
Study: NCT02170324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01860287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo
Study: NCT00642980
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Study: NCT00642980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Study: NCT00642980
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
Study: NCT02495129
Drug: VAY736 higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
Study: NCT01151176
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
Study: NCT01151176
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose \>141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; \> 400=16U
Study: NCT03764462
Drug: AD-101 45mg
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 45mg tablet
Study: NCT02752880
Drug: YH1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
Study: NCT02752880
Drug: placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
Study: NCT02252146
Drug: IMO-8400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MO-8400 given subcutaneously twice weekly
Study: NCT02488980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for three days followed by placebo once a week for 24 weeks
Study: NCT04333992
Drug: sevoflurane and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
Study: NCT01400776
Drug: WC3011 Estradiol Vaginal Cream
Normalized name: Estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
Study: NCT01400776
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
Study: NCT03648346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops
Study: NCT02797717
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARM B , 25mg/m2
Study: NCT02797717
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ARM A and ARM B , 625mg/m2 i.v
Study: NCT00184041
Drug: Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction I/II, consolidation I/II/III/IV and Maintenance
Study: NCT04651881
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Cap., single oral administration under fed condition
Study: NCT04651881
Drug: Test drug 1
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tab., single oral administration under fed condition
Study: NCT04651881
Drug: Test drug 2
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tab., single oral administration under fed condition
Study: NCT04001413
Drug: MEDI0457
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study
Study: NCT02583919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly dosing for 26 weeks
Study: NCT02566876
Drug: Mixture of three Bifidobacteria
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
Study: NCT01210976
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: nacl 0.9% coloured with thiamin in same volume and time than levosimendan
Study: NCT00655538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily for 36 weeks
Study: NCT03487731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
Study: NCT00481819
Drug: FK506MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00481819
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00502736
Drug: ibandronate [Bondronat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg iv on days 1-3
Study: NCT00812877
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulp capping agent, Calcium Hydroxide
Study: NCT00654368
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
Study: NCT01421017
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01364584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection 2.5 mcg-10 mcg BID
Study: NCT01439919
Drug: Placebo (for SSR411298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: tablet~Route: oral administration with food
Study: NCT02230735
Drug: Bipivacaine 0.5% with epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
Study: NCT02230735
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: (placebo for bupivacaine)
Study: NCT02464436
Drug: hRPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
Study: NCT00254137
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03901131
Drug: Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow clinical administration
Study: NCT03318835
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
Study: NCT02919774
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets
Study: NCT04557800
Drug: DNL151
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose(s)
Study: NCT04557800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose(s)
Study: NCT00831272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02249936
Drug: AZD1722
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03603184
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
Study: NCT00393848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Ketoconazole
Study: NCT02013830
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
Study: NCT02885805
Drug: BAY987516
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.00 mg/cm2 ± 0.04 mg/cm2
Study: NCT02885805
Drug: SPF 15 Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.00 mg/cm2 ± 0.04 mg/cm2
Study: NCT01349335
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, 30 mg, Qd, 7days.
Study: NCT02686385
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04513548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection every four weeks
Study: NCT00001716
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181309
Drug: Meloxicam, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02181309
Drug: Meloxicam, medium dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02181309
Drug: Meloxicam, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01609517
Drug: Spinal anesthesia (heavy bupivacaine)
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
Study: NCT01064817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
Study: NCT00136058
Drug: alendronate or risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006035
Drug: electroporation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01551056
Drug: AC-170 0.24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study: NCT01551056
Drug: AC-170 0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study: NCT00759161
Drug: AN2728
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2728 Ointment, 5%, twice daily for 4 weeks
Study: NCT00759161
Drug: AN2728 Ointment Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2728 Ointment Vehicle, twice daily for 4 weeks.
Study: NCT00804986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
Study: NCT01793441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in different stages of the study for 12 weeks.
Study: NCT01793441
Drug: RG7314
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
Study: NCT02832934
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study: NCT02832934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study: NCT01794000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00965081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD po at the same time each day for 12 weeks
Study: NCT03700801
Drug: Triple combination therapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
Study: NCT00738699
Drug: 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
Study: NCT01744249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
Study: NCT02432326
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
Study: NCT02432326
Drug: BBI503
Approvals — FDA: no, EMA: no, PMDA: no
Description: The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
Study: NCT01135134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF Placebo nasal spray and administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks
Study: NCT00407186
Drug: cisplatin+capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
Study: NCT00407186
Drug: epirubicin+cisplatin+capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
Study: NCT04030767
Drug: Botox Injectable Product
Normalized name: Botox Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
Study: NCT04033367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT03020745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is available as a Clear colorless solution.
Study: NCT03679065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Study: NCT03196310
Drug: Platelet Concentrate
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet Rich plasma
Study: NCT00989937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU BID or 40 IU BID
Study: NCT03008161
Drug: NPT088
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
Study: NCT03008161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04537793
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination granules for oral administration.
Study: NCT02057692
Drug: LUM001
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUM001 administered orally
Study: NCT02057692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally
Study: NCT01727128
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00860353
Drug: AZD2551
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral solution.
Study: NCT00860353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral solution
Study: NCT02859246
Drug: Mucinex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucinex®